Developing the risk prediction model (ProlncSig) from lipoxygenase pathway-related lncRNAs for prognosis prediction in breast cancer

Alterations in cellular metabolism are known to play a crucial role in the development and progression of cancer. The lipoxygenase pathway, which controls unsaturated fatty acid metabolism, has been shown to regulate tumour progression and is commonly altered in breast cancer. In this study, we firs...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiaoyu Fu, Weixing Wang, Bradley M. Downs, Juanjuan Li
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:RNA Biology
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/15476286.2025.2544440
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849339584275546112
author Xiaoyu Fu
Weixing Wang
Bradley M. Downs
Juanjuan Li
author_facet Xiaoyu Fu
Weixing Wang
Bradley M. Downs
Juanjuan Li
author_sort Xiaoyu Fu
collection DOAJ
description Alterations in cellular metabolism are known to play a crucial role in the development and progression of cancer. The lipoxygenase pathway, which controls unsaturated fatty acid metabolism, has been shown to regulate tumour progression and is commonly altered in breast cancer. In this study, we first obtained 11 lipoxygenase pathway genes from the Molecular Signatures Database (MSigDB). We then explored the lipoxygenase pathway-related long non-coding RNAs (lncRNAs) in breast cancer tissues from The Cancer Genome Atlas (TCGA) database. Information from our analysis was used to construct a risk prediction model (ProlncSig) to predict breast cancer prognosis. We found that ProlncSig could accurately identify breast cancer patients that had significantly shorter overall survival from those that had longer overall survival. Moreover, ProlncSig performs better in predicting prognosis than the clinicopathological features. Furthermore, GO and KEGG enrichment analysis showed that ProlncSig risk score had a high correlation with immune signature. We developed and validated an accurate prognostic risk prediction model (ProlncSig) based on lipoxygenase pathway-related lncRNAs, which has strong potential to provide prognostic information and may provide novel guidance for immunotherapeutic strategies for breast cancer patients.
format Article
id doaj-art-a0eb6eca87f346888677d62c9bf16e98
institution Kabale University
issn 1547-6286
1555-8584
language English
publishDate 2025-12-01
publisher Taylor & Francis Group
record_format Article
series RNA Biology
spelling doaj-art-a0eb6eca87f346888677d62c9bf16e982025-08-20T03:44:06ZengTaylor & Francis GroupRNA Biology1547-62861555-85842025-12-0122111910.1080/15476286.2025.2544440Developing the risk prediction model (ProlncSig) from lipoxygenase pathway-related lncRNAs for prognosis prediction in breast cancerXiaoyu Fu0Weixing Wang1Bradley M. Downs2Juanjuan Li3Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, ChinaDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USABreast Cancer Center, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, National Key Clinical Specialty Construction Discipline, Hubei Provincial Clinical Research Center for Breast Cancer, Wuhan Clinical Research Center for Breast Cancer, Wuhan, ChinaDepartment of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, ChinaAlterations in cellular metabolism are known to play a crucial role in the development and progression of cancer. The lipoxygenase pathway, which controls unsaturated fatty acid metabolism, has been shown to regulate tumour progression and is commonly altered in breast cancer. In this study, we first obtained 11 lipoxygenase pathway genes from the Molecular Signatures Database (MSigDB). We then explored the lipoxygenase pathway-related long non-coding RNAs (lncRNAs) in breast cancer tissues from The Cancer Genome Atlas (TCGA) database. Information from our analysis was used to construct a risk prediction model (ProlncSig) to predict breast cancer prognosis. We found that ProlncSig could accurately identify breast cancer patients that had significantly shorter overall survival from those that had longer overall survival. Moreover, ProlncSig performs better in predicting prognosis than the clinicopathological features. Furthermore, GO and KEGG enrichment analysis showed that ProlncSig risk score had a high correlation with immune signature. We developed and validated an accurate prognostic risk prediction model (ProlncSig) based on lipoxygenase pathway-related lncRNAs, which has strong potential to provide prognostic information and may provide novel guidance for immunotherapeutic strategies for breast cancer patients.https://www.tandfonline.com/doi/10.1080/15476286.2025.2544440LipoxygenasesLncRNAprognostic signaturetumour immunityImmunotherapybreast cancer
spellingShingle Xiaoyu Fu
Weixing Wang
Bradley M. Downs
Juanjuan Li
Developing the risk prediction model (ProlncSig) from lipoxygenase pathway-related lncRNAs for prognosis prediction in breast cancer
RNA Biology
Lipoxygenases
LncRNA
prognostic signature
tumour immunity
Immunotherapy
breast cancer
title Developing the risk prediction model (ProlncSig) from lipoxygenase pathway-related lncRNAs for prognosis prediction in breast cancer
title_full Developing the risk prediction model (ProlncSig) from lipoxygenase pathway-related lncRNAs for prognosis prediction in breast cancer
title_fullStr Developing the risk prediction model (ProlncSig) from lipoxygenase pathway-related lncRNAs for prognosis prediction in breast cancer
title_full_unstemmed Developing the risk prediction model (ProlncSig) from lipoxygenase pathway-related lncRNAs for prognosis prediction in breast cancer
title_short Developing the risk prediction model (ProlncSig) from lipoxygenase pathway-related lncRNAs for prognosis prediction in breast cancer
title_sort developing the risk prediction model prolncsig from lipoxygenase pathway related lncrnas for prognosis prediction in breast cancer
topic Lipoxygenases
LncRNA
prognostic signature
tumour immunity
Immunotherapy
breast cancer
url https://www.tandfonline.com/doi/10.1080/15476286.2025.2544440
work_keys_str_mv AT xiaoyufu developingtheriskpredictionmodelprolncsigfromlipoxygenasepathwayrelatedlncrnasforprognosispredictioninbreastcancer
AT weixingwang developingtheriskpredictionmodelprolncsigfromlipoxygenasepathwayrelatedlncrnasforprognosispredictioninbreastcancer
AT bradleymdowns developingtheriskpredictionmodelprolncsigfromlipoxygenasepathwayrelatedlncrnasforprognosispredictioninbreastcancer
AT juanjuanli developingtheriskpredictionmodelprolncsigfromlipoxygenasepathwayrelatedlncrnasforprognosispredictioninbreastcancer